Nexcella, Immix Biopharma Subsidiary, to Present at the

LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage...

Related Keywords

California ,United States ,Mike Moyer ,Los Angeles ,Ilya Rachman ,Gabriel Morris ,Immix Biopharma Inc ,Company Conference ,Nexcella Inc ,Nasdaq ,Exchange Commission ,Chief Executive Officer ,Chief Financial Officer ,Immix Biopharma ,Tissue Specific Therapeutics ,Tissue Specific Therapeutic ,Orphan Drug Designation ,Rare Pediatric Disease Designation ,Risk Factor ,Annual Report ,Nasdaq Immx ,Nc ,Nexcella ,